Matthew Ferriday

Matthew Ferriday is an experienced leader in the biopharmaceutical industry with a focus on neuroscience, rare diseases, and vaccines. Currently serving as Head of Neuroscience and Rare Diseases at Ipsen since November 2023, Matthew oversees full P&L responsibilities and has successfully launched a first-in-class treatment for primary biliary cholangitis. Previously, as Business Unit Director at AstraZeneca, Matthew led a business unit with substantial revenues and played a pivotal role in developing strategies for COVID monoclonal antibodies. Matthew's earlier roles at GSK included Business Unit Director for the Australian Respiratory business, Global Marketing Director for Biologics, and various commercial leadership positions that contributed to substantial portfolio growth. Matthew's career began at ViiV Healthcare, where significant achievements included leading sales and strategic market expansions. Matthew holds a BSc in Pharmacology from the University of Leeds.